In a patient with myelodysplastic syndrome and low hemoglobin, hematocrit, red blood cell count, white blood cell count, and platelet count, what blood components should be transfused?

Transfusion Management in Pancytopenic Myelodysplastic Syndrome

In MDS patients with pancytopenia, transfuse red blood cells to maintain hemoglobin ≥8 g/dL (or 9-10 g/dL with cardiovascular comorbidities), provide platelet transfusions only for active bleeding or severe thrombocytopenia with bleeding risk, and use G-CSF only during active severe infections with neutropenia—not prophylactically. 1

Red Blood Cell Transfusion Strategy

Primary approach:

• Transfuse RBC concentrates (leukocyte-reduced, CMV-safe) to maintain hemoglobin at least 8 g/dL in stable patients 1, 2
• Increase the threshold to 9-10 g/dL in patients with cardiovascular comorbidities or poor functional tolerance 1, 2
• Consider administering sufficient RBC units over 2-3 days to increase hemoglobin above 10 g/dL to limit chronic anemia effects on quality of life 1, 2

Special considerations:

• Use CMV-negative blood products whenever possible for CMV-negative recipients 2
• Irradiate all directed-donor products and transfusions for potential stem cell transplant candidates 2
• Monitor for transfusion-associated circulatory overload (TACO), which is the leading fatal complication in MDS patients—use slow transfusion rates and rigorous blood pressure monitoring in this high-risk elderly population with cardiac comorbidities 3

Platelet Transfusion Approach

Key principle: Prophylactic platelet transfusions are generally NOT used long-term in MDS except when receiving myelosuppressive drugs 1

Transfuse platelets only when:

• Severe thrombocytopenia with active bleeding occurs 1, 2
• Clinically indicated bleeding complications develop 1

For refractory bleeding:

• Consider aminocaproic acid or other antifibrinolytic agents for bleeding refractory to platelet transfusions or profound thrombocytopenia 2

White Blood Cell/Neutropenia Management

Critical distinction: G-CSF use is infection-driven, not prophylactic 1

Appropriate G-CSF use:

• Initiate broad-spectrum antibiotics immediately for any fever or symptoms of infection in neutropenic patients—this is mandatory 1, 2
• Add G-CSF during severe active infections with neutropenia 1, 2
• G-CSF improves neutropenia in 60-75% of cases during infections 1

What NOT to do:

• Do not use prolonged prophylactic G-CSF—it has not demonstrated survival impact in MDS patients 1
• Never delay broad-spectrum antibiotics in febrile neutropenic patients 1

Monitoring and Complications

Essential monitoring:

• Monitor serum ferritin levels in chronically transfused patients, as iron overload contributes to increased mortality and morbidity 2
• Watch for citrate toxicity (hypocalcemia, hypomagnesemia) when multiple transfusion units are given rapidly 1, 2
• Reassess hemoglobin and symptoms after each transfusion unit 1, 2

Common pitfall: Higher pretransfusion RBC and platelet transfusion burden is independently associated with higher overall mortality, relapse-related mortality, and lower hematopoietic recovery after allogeneic transplantation 4. This underscores the importance of considering early allogeneic transplantation for patients requiring repeated transfusions rather than indefinite transfusion support.

Disease Reassessment During Acute Decompensation

When cytopenias worsen:

• Perform complete blood count with platelets and repeat bone marrow examination if there is concern for disease progression to higher-risk MDS or AML transformation 1
• Reassess IPSS-R risk category to determine whether treatment escalation is needed 1
• For progression to higher-risk disease, azacitidine 75 mg/m² subcutaneously for 7 consecutive days every 28 days is the first-line reference treatment, with at least 6 cycles recommended 1